Previous 10 | Next 10 |
- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV ® sales - Second half fiscal 2021 revenues grew 10% over 2020, while total new enrollments grew 24% as commercial execution strategy firmly carries momentum into 2022 - Lead onc...
No difference in pharmacokinetics between IV Push and IV Infusion No serious adverse events observed No difference in viral load between IV Push and IV Infusion and no anti-drug antibodies detected MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies I...
- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization - Higher employee engagement and retention, greater ability to attract top talent and lower tur...
MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter...
MONTREAL, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics...
MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovatio...
Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended Canada NewsWire MONTREAL , Nov. 23, 2021 /CNW Telbec/ - Theratechnologies Inc. (" Theratechnologies " or the " Company ...
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, w...
MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Med...
MONTREAL, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the publication of a peer-reviewed articl...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...